Last reviewed · How we verify
NCT05762029
Treatment of Extracorporeal Membrane Oxygenation in Severe Poisoning
trial in Poison;Medicinal in 60 participants. Status unknown.
26 November 2025
Quick facts
| Lead sponsor | Affiliated Hospital of Nantong University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 26 November 2022 |
| Primary completion | 26 November 2025 |
| Estimated completion | 26 November 2025 |
| Sites | 1 location across China |
Conditions studied
- Poison;Medicinal — all drugs for Poison;Medicinal →
- Extracorporeal Membrane Oxygenation — all drugs for Extracorporeal Membrane Oxygenation →
Sponsor
Affiliated Hospital of Nantong University
Who can join
14 and older, any sex, with Poison;Medicinal or Extracorporeal Membrane Oxygenation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, multicentre clinical study to determine the value of the Extracorporeal Membrane Oxygenation in the treatment of critically ill poisoning patients and whether there are significant differences in the prognosis of different types or doses of poison/drug poisoning. These conclusions may guide us on how to correctly perform Extracorporeal Membrane Oxygenation, including whether or when should this treatment enabled, the mode of Extracorporeal Membrane Oxygenation, whether to combine blood purification, treatment schedule and disembarkation time.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05762029
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Affiliated Hospital of Nantong University trials
Trials by the same sponsor.
- NCT07506668 — RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas · Phase 1, PHASE2 · not yet recruiting
- NCT07342283 — QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer · Phase 2 · recruiting
- NCT07382453 — Effect of PAE Hydrogel Loaded With tRF-ASO-Exo on Patients With Diabetic Ocular Surface Diseases · Phase 2 · not yet recruiting
- NCT07247838 — Prospective Cohort Control Study on Changes in Gut Microbiota in Ischemic Stroke · recruiting
- NCT07271147 — Effects of taVNS Combined With Dexmedetomidine on POVN · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05762029 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Affiliated Hospital of Nantong University
- Last refreshed: 9 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05762029.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing